A public economics framework is used to consider how pharmaceuticals should be priced when at least some of the research and development incentive comes from sales revenues. Familiar techniques of public finance are used to relax some of the restrictions implied in the standard use of Ramsey pricing. Under the more general model, poor countries should not necessarily cover even their own marginal costs, and the pricing structure is not related to...
انظر المزيد
تفاصيل
-
2005/1/01
-
مقال بمجلة علمية
-
77482
-
1
-
1
-
2013/5/23
-
Disclosed
-
Financing pharmaceutical innovation : how much should poor countries contribute?
-
marginal cost of production
تنزيل الملفات
تقرير كامل
نسخة رسمية من الوثيقة (قد تضم توقيعات، الخ)
-
Total Downloads** : 203